Distinct qualitative differences between normal and abnormal hemopoietic stem cells in vivo and in vitro
- PMID: 9007223
- DOI: 10.1002/stem.150056
Distinct qualitative differences between normal and abnormal hemopoietic stem cells in vivo and in vitro
Abstract
The transplantation of partially purified hemopoietic stem cells (HSCs) plus the engraftment of bone from autoimmune-prone mice ((NZW x BXSB)F1 (W/BF1) mice) induces autoimmune diseases in major histocompatibility complex (MHC)-incompatible normal C3H/HeN mice. In contrast, W/BF1 mice die of infection or anemia within three weeks due to a failure in hemopoietic reconstitution when the mice receive partially purified HSCs plus bones from normal C3H/HeN mice, although they survive more than a year without showing any symptoms of autoimmune diseases when they receive T cell-depleted bone marrow cells (without bone grafts) from normal mice. This finding suggests that abnormal HSCs can proliferate even in MHC-incompatible microenvironments, while normal HSCs cannot. This is confirmed by spleen colony-forming assays (CFU-S) on day 12, using pluripotent HSCs (P-HSCs). The P-HSCs of old (> 4 mo) W/BF1 mice (after the development of autoimmune diseases) form high CFU-S counts on day 12 even in the allogeneic C3H environment, although the P-HSCs of normal mice form high CFU-S counts only in the MHC-compatible environments. In addition, abnormal P-HSCs of autoimmune-prone mice can proliferate in vitro in collaboration with MHC-incompatible stromal cells, although normal HSCs do so in collaboration with MHC-compatible stromal cells, but not MHC-incompatible stromal cells. These findings indicate that abnormal P-HSCs are more "resilient" than normal P-HSCs.
Similar articles
-
Age-dependent abnormalities of hematopoietic stem cells in (NZW x BXSB)F1 mice.Stem Cells. 1999;17(6):357-65. doi: 10.1002/stem.170357. Stem Cells. 1999. PMID: 10606164
-
Requirement of major histocompatibility complex-compatible microenvironment for spleen colony formation (CFU-S on day 12 but not on day 8).Stem Cells. 1997;15(6):461-8. doi: 10.1002/stem.150461. Stem Cells. 1997. PMID: 9402659
-
Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor.J Immunol. 1994 Mar 15;152(6):3119-27. J Immunol. 1994. PMID: 8144907
-
Bone marrow transplantation for autoimmune diseases.Acta Haematol. 1998;99(3):116-32. doi: 10.1159/000040826. Acta Haematol. 1998. PMID: 9587393 Review.
-
Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment (Review).Int J Mol Med. 1998 Jan;1(1):5-16. doi: 10.3892/ijmm.1.1.5. Int J Mol Med. 1998. PMID: 9852193 Review.
Cited by
-
Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis.Curr Allergy Asthma Rep. 2021 Mar 24;21(3):22. doi: 10.1007/s11882-021-00996-y. Curr Allergy Asthma Rep. 2021. PMID: 33759038 Review.
-
The future of stem cell transplantation in autoimmune disease.Clin Rev Allergy Immunol. 2010 Apr;38(2-3):292-7. doi: 10.1007/s12016-009-8159-5. Clin Rev Allergy Immunol. 2010. PMID: 19609732 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials